ene linked to obesity – Friedman predicts that more will come to light – but it does play a leading role, and will certainly be important in future drug therapies against obesity: "There is a lot left to be learned about the regulation of obesity, but the identification of leptin will undoubtedly lead us to a better understanding of the factors controlling appetite, which will lead, in turn, to new avenues for treatment."
For Friedman, however, the objective is not to get everyone who is obese to lose weight, but "to make unhealthy people healthier." And this, he points out, can be achieved with even moderate weight loss.BiographiesDouglas L Coleman was born in Ontario, Canada, in 1931. After attending elementary and secondary schools in the town of Stratford, he went on to McMaster University, Hamilton, Ontario, where he received a BSc in chemistry. Coleman then continued his studies in the United States, at the University of Wisconsin, obtaining his doctorate there in 1958.
That same year he joined the staff of The Jackson Laboratory and, although his original intention was to stay for just a couple of years, he would end up spending his entire research career with this institution. He retired in 1991 and, since then, has devoted much of his time to ecological issues like forest management and land conservation, with the same enthusiasm he brought to research.
Jeffrey M. Friedman was born in Orlando, Florida, United States, in 1954, but was brought up in the suburbs of New York City. His father was a radiologist and his mother a teacher. He finished polytechnic studies in 1971 and went on to complete an MD at Union University in 1977. During his medical studies he got his first taste of research, and soon took up a recoPage: 1 2 3 4 5 6 7 8 9 Related biology technology :1
. BBVA Foundation Unites the Efforts of Massachusetts General Hospital and Barcelonas Vall dHebron Hospital in Biomarker Research for Personalized Cancer Therapies2
. Leaders in Science Join Upcoming Celebration of the 100th Anniversary of the Oldest Science Foundation in America3
. Silence Therapeutics Announces Positive Response by USPTO that Affirms Validity of Four Foundational RNAi Patents4
. Cord Blood America Announces Exclusive Agreement With National Childrens Leukemia Foundation to Store Stem Cells5
. Elsevier Foundation Awards 2011 Grants to Advance Women in Science and Support Libraries in Developing Countries6
. Galien Foundation Announces 2012 Awards Program For Best Biopharmaceutical Products and Best Medical Technology7
. Foundation for Angelman Syndrome Therapeutics (FAST) Funds Human Clinical Trial8
. NeuroPhage Receives Michael J. Fox Foundation Funding for Parkinsons Disease Research9
. Foundation of UMDNJ Receives Grand Challenges Tuberculosis Biomarkers Grant10
. Foundation for Health Improvement and Technology (FHIT) Launched to Beat Cardiovascular Disease11
. Systems Alliance Launches Redesigned Website for The Living Legacy Foundation of Maryland